Xoma (XOMA) to Report Q4 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 03/02/21
XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital ConferencesGlobeNewsWire • 01/04/21
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock OfferingGlobeNewsWire • 12/21/20
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred StockGlobeNewsWire • 12/10/20
XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 DevelopmentGlobeNewsWire • 11/16/20
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial ResultsGlobeNewsWire • 11/05/20
XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic AllianceGlobeNewsWire • 11/03/20
XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic CancerGlobeNewsWire • 10/28/20
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/28/20
Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing AgreementGlobeNewsWire • 03/09/20
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/27/20